Andrew de Guttadauro

Andrew de Guttadauro is a proven biopharmaceutical executive with more than 30 years of experience successfully leading business development, commercialization, and corporate strategy teams focusing on both domestic and global markets. Andrew has helped build and scale organizations ranging from top ten multinational biopharma companies to emerging startups, consistently driving growth through strategic partnerships, licensing, and commercial excellence. His work encompasses multiple therapeutic segments including oncology, immunology, infectious disease, and primary care.

Andrew’s startup business development and fundraising experience includes roles as Chief Business Officer at Saravir Biopharma and, previously, at Phoenix Molecular Designs. As Vice President of Business Development at Oncolytics Biotech and, previously, at Vical Incorporated, Andrew successfully secured partnerships with top ten biopharma companies and expanded collaborations with multiple existing large pharma companies.

Prior to transitioning to business development roles, Andrew held national and regional commercial executive roles. In his commercial capacity, Andrew led and contributed to the successful launches of multiple blockbusters in oncology, inflammation, and gastroenterology therapeutic segments.

Andrew provides strategic and operational guidance to biopharma startups, with a focus on business development, fundraising, and commercial scale-up. His support has resulted in the acceleration of clinical and commercial development for multiple biotechnology startup companies.

Driven by a passion for advancing breakthrough therapies and building sustainable value, Andrew brings a unique combination of scientific insight, commercial acumen, and global business leadership to every engagement.

Andrew holds a Bachelor of Science in Engineering from the U.S. Military Academy at West Point.